Cargando…

Yokukansan and its ingredients as possible treatment options for schizophrenia

Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire range of human mental function. The devastating effect of the illness is usually long-lasting and requires lifelong treatment. Despite an evolved psychopharmacological understanding, the overall therapeutic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chuan-Hsun, Ishii, Ryouhei, Yu, Shun-Chieh, Takeda, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156002/
https://www.ncbi.nlm.nih.gov/pubmed/25210456
http://dx.doi.org/10.2147/NDT.S67607
_version_ 1782333671983808512
author Yu, Chuan-Hsun
Ishii, Ryouhei
Yu, Shun-Chieh
Takeda, Masatoshi
author_facet Yu, Chuan-Hsun
Ishii, Ryouhei
Yu, Shun-Chieh
Takeda, Masatoshi
author_sort Yu, Chuan-Hsun
collection PubMed
description Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire range of human mental function. The devastating effect of the illness is usually long-lasting and requires lifelong treatment. Despite an evolved psychopharmacological understanding, the overall therapeutic effect of antipsychotics is still not satisfactory. The choice of proper medication presents a clinical dilemma between efficacy and safety. As a result, searching for comparable treatment options with safer profiles is very important. Yokukansan (TJ-54), also called yi-gan san in Chinese, is a traditional herbal medicine with evident therapeutic effect for neuropsychiatric disorders. There are several open-label clinical studies upholding the possibility of using yokukansan to treat schizophrenia or schizophrenia-like psychosis. Evidence from animal studies and neurobiology also sheds light on the antipsychotic implications of yokukansan and its ingredients. Nevertheless, correlations between the experimental environment and clinical settings may be complicated by a number of confounders. Clinical trials with more sophisticated designs are required to fill the gap between the experimental environment and clinical settings.
format Online
Article
Text
id pubmed-4156002
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41560022014-09-10 Yokukansan and its ingredients as possible treatment options for schizophrenia Yu, Chuan-Hsun Ishii, Ryouhei Yu, Shun-Chieh Takeda, Masatoshi Neuropsychiatr Dis Treat Review Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire range of human mental function. The devastating effect of the illness is usually long-lasting and requires lifelong treatment. Despite an evolved psychopharmacological understanding, the overall therapeutic effect of antipsychotics is still not satisfactory. The choice of proper medication presents a clinical dilemma between efficacy and safety. As a result, searching for comparable treatment options with safer profiles is very important. Yokukansan (TJ-54), also called yi-gan san in Chinese, is a traditional herbal medicine with evident therapeutic effect for neuropsychiatric disorders. There are several open-label clinical studies upholding the possibility of using yokukansan to treat schizophrenia or schizophrenia-like psychosis. Evidence from animal studies and neurobiology also sheds light on the antipsychotic implications of yokukansan and its ingredients. Nevertheless, correlations between the experimental environment and clinical settings may be complicated by a number of confounders. Clinical trials with more sophisticated designs are required to fill the gap between the experimental environment and clinical settings. Dove Medical Press 2014-09-01 /pmc/articles/PMC4156002/ /pubmed/25210456 http://dx.doi.org/10.2147/NDT.S67607 Text en © 2014 Yu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Yu, Chuan-Hsun
Ishii, Ryouhei
Yu, Shun-Chieh
Takeda, Masatoshi
Yokukansan and its ingredients as possible treatment options for schizophrenia
title Yokukansan and its ingredients as possible treatment options for schizophrenia
title_full Yokukansan and its ingredients as possible treatment options for schizophrenia
title_fullStr Yokukansan and its ingredients as possible treatment options for schizophrenia
title_full_unstemmed Yokukansan and its ingredients as possible treatment options for schizophrenia
title_short Yokukansan and its ingredients as possible treatment options for schizophrenia
title_sort yokukansan and its ingredients as possible treatment options for schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156002/
https://www.ncbi.nlm.nih.gov/pubmed/25210456
http://dx.doi.org/10.2147/NDT.S67607
work_keys_str_mv AT yuchuanhsun yokukansananditsingredientsaspossibletreatmentoptionsforschizophrenia
AT ishiiryouhei yokukansananditsingredientsaspossibletreatmentoptionsforschizophrenia
AT yushunchieh yokukansananditsingredientsaspossibletreatmentoptionsforschizophrenia
AT takedamasatoshi yokukansananditsingredientsaspossibletreatmentoptionsforschizophrenia